Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 浙江东方基因生物制品股份有限公司成立于2005年12月,是一家专业从事体外诊断产品研发、生产与销售的公司,属于高端医疗设备与器械领域。目前主营产品POCT即时诊断试剂,主要应用于传染病检测(含新冠病毒检测产品)、毒品检测、优生优育检测、肿瘤标志物检测和心肌标志物检测等领域,其中传染病检测和毒品检测作为公司的两大核心产品系列。公司销售网络深入120多个国家和地区,2019年境外销售收入占比95%,目前公司已取得境外认证/备案300余项,国内注册/备案证书70余项。除POCT即时诊断试剂外,公司根据研发领域和方向,持续投入生物原料平台、分子诊断平台、液态生物芯片平台和体外诊断仪器平台的研发,制定各技术平台同步发展的战略,以集成研发的模式推进公司发展。公司一直秉承全球化发展战略,现已发展成为一家享有较高国际知名度的医疗器械企业。
Main Business 体外诊断产品的研发、生产与销售
Legal Representative 方剑秋
Top Executives
董事长：方剑秋
董事：方新成,严路易,方剑秋,方效良
独立董事：张红英,王晓燕,李波
Top 5 Shareholder
Shareholder name Nature Holding Date
安吉福浪莱进出口贸易有限公司流通A股19.50%30/09/2024
Fangs Holdings Limited Liability Company流通A股18.75%30/09/2024
安吉涌威创业投资合伙企业（有限合伙）流通A股10.31%30/09/2024
招商银行股份有限公司－广发价值核心混合型证券投资基金流通A股1.95%30/09/2024
香港中央结算有限公司流通A股1.60%30/09/2024
Company Secretary 章叶平
Solicitors 国浩律师（杭州）事务所
Auditors 立信会计师事务所（特殊普通合伙）
Tel No 0572-5300267
Fax No 0572-5228933
Website www.orientgene.com
Email zqb@orientgene.com
Company Address
Register: 浙江省湖州市安吉县递铺街道阳光大道东段3787号
Office: 浙江省湖州市安吉县递铺街道阳光大道东段3787号
Listing Date 05/02/2020
Shares Capital
Shares Capital: 201,600,000
Total A Share: 201,600,000
Listed A Share: 201,600,000
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ -1.970
DPS(RMB)* --
NBV Per Share(RMB)* ¥ 36.885
Market Capitalization(RMB) 6.883B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.